Swamy Yeleswaram
Vermogen: 10 M $ op 31-05-2026
Vermogen: 10 M $ op 31-05-2026
Swamy Yeleswaram was the founder of Incyte Corp., founded in 2002, and held the title of Group Vice President-Drug Metabolism from 2016 to 2022.
Dr. Yeleswaram currently holds the position of Chief Development Officer at Rapport Therapeutics, Inc. since 2023.
Dr. Yeleswaram's education includes a doctorate from the University of British Columbia, a graduate degree from Banaras Hindu University, and an undergraduate degree from Madras Medical College.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 17-04-2026 | 246.426 ( 0,52% ) | 10 M $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| RAPPORT THERAPEUTICS, INC. | Corporate Officer/Principal | 01-01-2023 |
| Bedrijven | Functie | Einde |
|---|---|---|
| INCYTE CORPORATION | Oprichter | 01-08-2022 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 5 |
|---|---|
Incyte Corp.
Incyte Corp. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of proprietary therapeutics | Health Technology |
University of British Columbia
University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Banaras Hindu University
Banaras Hindu University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Madras Medical College
Madras Medical College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. BiotechnologyHealth Technology Operates as an clinical-stage biotechnology company that engages in discovery and development of medicines for neurological disorder | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau